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Abstract 17 
Background: The workflow used for the discovery of novel milk protein-derived bioactive 18 
peptides (BAPs) has significantly evolved over the past number of years. Many of the 19 
approaches currently described in the literature for the study of milk protein-derived BAPs have 20 
taken similar routes as those conventionally used in drug discovery. However, because milk 21 
protein-derived BAPs are prepared from dietary sources and in a food-grade manner, they differ 22 
from drugs in that they are generally present in a complex mixture as opposed to drug active 23 
compounds which are generally synthetically produced, having a relatively high level of purity. 24 
Scope and approach: This review assesses the utilisation of drug discovery methods for the 25 
identification of novel milk protein-derived BAPs. Different methods relevant to drug discovery 26 
have already proven effective for the discovery of new BAPs from milk proteins. 27 
Key findings and conclusions: However, reversing the workflow, starting from peptide 28 
identification in vivo to in vitro screening followed by conventional drug discovery approaches 29 
may have several merits. These include (a) the design of more targeted studies, (b) the 30 
development of novel approaches for the generation of milk protein hydrolysates and (c) the 31 
discovery of milk BAPs which may be bioavailable in humans. These BAPs may find 32 
applications in the commercial generation of dietary ingredients with health promoting effects 33 
in humans. 34 
 35 
Key words: milk proteins; bioactive peptides; drug discovery; in silico; quantitative structure 36 
activity relationship (QSAR); human studies. 37 
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1 Introduction 38 
Food protein-derived bioactive peptides (BAPs) have been extensively studied in relation to their 39 
potential health promoting effects in humans. A large number of studies have been conducted 40 
with milk protein-derived BAPs (for reviews, see: Hernández-Ledesma, García-Nebot, 41 
Fernández-Tomé, Amigo, & Recio, 2014; Nongonierma & FitzGerald, 2015b). 42 
Despite major advances in medical and pharmaceutical sciences, as well as a broader access to 43 
health structures in certain countries, specific metabolic diseases now appear to be more 44 
prevalent worldwide. The metabolic syndrome (MetS) is defined as a combination of risk factors 45 
including abdominal obesity, insulin resistance along with high cholesterolemia and blood 46 
pressure (BP). It is estimated that ~ 25% of the world’s population is affected by the MetS (IDF, 47 
2006). Different strategies to manage the complications of the MetS (i.e., cardiovascular diseases 48 
(CVDs), type 2 diabetes (T2D) and obesity) have been proposed. Lifestyle modifications (dietary 49 
interventions and participation in physical activity) and/or medication are often recommended as 50 
preventative and curative approaches. However, the use of pharmaceutical drugs is sometimes 51 
associated with side-effects, for this reason, the search for natural alternatives originating from 52 
foods/dietary compounds has increased (Li-Chan, 2015). In this context, scientifically validated 53 
milk protein-derived BAPs have the potential to be formulated into foods to provide their health 54 
promoting properties to the general population. 55 
The aim of this review was to assess current strategies for milk protein-derived BAP discovery. 56 
To date, it appears that numerous methodologies directly arising from drug discovery approaches 57 
have been applied to selected BAPs. An attempt to understand the limitations of using a 58 
conventional drug discovery approach for studying milk protein-derived BAPs has been carried 59 
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out herein. Finally, an alternative strategy is outlined which may be beneficial to increasing the 60 
rate of discovery of novel BAP sequences targeting specific human disease/health conditions. 61 
2 General workflow for drug discovery and parallels with milk BAP 62 
generation, identification and validation 63 
Modern drug discovery has been described as being mainly based on targeted therapeutics and 64 
biomarkers (Qin et al., 2014). Drug discovery comprises several steps (Fig. 1) including the 65 
identification of specific targets to allow screening for the selection of potential pharmacological 66 
compounds. The promising candidate(s) are then assessed for safety, bioavailability and potency, 67 
parameters which are generally determined in cell culture and animal models. The molecules are 68 
subsequently evaluated in different human intervention studies before going through an approval 69 
phase by the relevant regulatory body. The analogy of a funnel may be applied to the drug 70 
discovery process, with the number of promising candidates (> 1,000) being decreased at each 71 
step (i.e., compound selection, screening, selection of target compounds, animal studies, human 72 
studies and regulatory approval) of the process (Fig. 1) to finally select one drug. 73 
In terms of milk protein-derived BAPs, only three groups of compounds appear, to date, to have 74 
gone through the whole cycle of the drug discovery workflow. These are 75 
caseinophosphopeptides (CPPs, e.g., amorphous calcium phosphate (ACP)-CPP), opioid 76 
peptides (e.g., -caseinomorphin 7 (Tyr-Pro-Phe-Pro-Gly-Pro-Ile)) and angiotensin converting 77 
enzyme (ACE) inhibitory peptides (i.e., the C12 peptide (Phe-Phe-Val-Ala-Pro-Phe-Pro-Glu-78 
Val-Phe-Gly-Lys, s1-casein (CN) (f 23-34) and the lactotripeptides (LTPs) Ile-Pro-Pro (-CN (f 79 
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74-76) and -CN (f 108-110)) and Val-Pro-Pro (-CN (f 84-86))) (Nongonierma & FitzGerald, 80 
2015c). 81 
The major difference between drugs and milk protein-derived BAPs is in their relative potency 82 
and the limited number of chemical structures which are available in terms of BAPs. In addition, 83 
differences in purity also exist between pharmaceutical drugs and milk protein-derived BAPs 84 
which are generally present as relatively complex mixtures of compounds (i.e., in hydrolysates or 85 
fermentates). For this reason, the base of the funnel in Fig. 1 is wider for milk BAPs as compared 86 
to drugs. Furthermore, synthetic drugs are normally not present within the human body unless 87 
they are intentionally administered. On the other hand, BAPs may be present in humans as they 88 
may arise from digestion of food (Boutrou et al., 2013) or from gastrointestinal (GI) endogenous 89 
proteins (Dave, Montoya, Rutherfurd, & Moughan, 2014). These differences may bring 90 
additional challenges to the discovery of milk BAPs and to the evaluation of their efficacy in 91 
humans (Nongonierma & FitzGerald, 2015c). 92 
Numerous drugs have been successfully developed, validated, and approved for disease 93 
management. On the other hand, milk BAPs are not meant to replace pharmaceutical drugs but 94 
rather to be utilised as disease prophylactic agents. In contrast, while a number of milk protein-95 
derived BAPs appear to have been scientifically validated in terms of health enhancement, their 96 
regulatory approval still represents a major hurdle (Fig. 1). 97 
3 Identification and validation of health targets 98 
The first step in the drug discovery process consists in the identification and validation of 99 
specific health targets (Fig. 1). Similar to the process of drug discovery, health targets of milk 100 
BAPs are selected using various rationales. These generally take into account the global 101 
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prevalence of diseases, the requirement for novel compounds targeting the disease (e.g., to 102 
increase the potency, reduce the side-effects or improve the sensory characteristics and stability 103 
of the molecule) along with economic drivers.  104 
The targets for specific diseases, together with the corresponding drugs, have been compiled in 105 
databases (Table 1) such as the Therapeutic Target Database (TTD, 106 
http://bidd.nus.edu.sg/group/TTD/ttd.asp) and the Drug Bank (http://www.drugbank.ca/). 107 
Additional information on clinical trials conducted with specific drugs are currently available on 108 
the web portal ClinicalTrials.gov (https://clinicaltrials.gov/) which comprises the results of > 109 
190,000 completed or on-going human clinical trials. 110 
Several milk protein-derived peptides have been discovered using similar targets as those 111 
employed in drug discovery. Table 2 contains a list of in vitro targets which have been used to 112 
evaluate the health enhancing properties of milk protein-derived BAPs. These targets include 113 
metabolic enzymes (i.e., ACE, dipeptidyl peptidase-IV (DPP-IV), -glucosidase), various 114 
markers of health and disease (i.e., cytokine level, glycaemia, cholesterolemia) or morphological 115 
modifications in humans (e.g., muscle mass gain, fat mass loss). For certain health conditions, 116 
multiple targets have been described. For example, hypotensive peptides can target in vitro ACE 117 
and renin inhibition, as well as different antioxidant markers (reactive oxygen species - ROS, 118 
oxidised lipids, etc.). 119 
4 Identification and generation of the peptide candidates 120 
Following selection of the health target(s), the next step in drug discovery consists in generation 121 
and compound screening (Fig. 1). In drug discovery, the target compounds which are selected for 122 
subsequent screening often originate from a well-known molecule which has previously been 123 
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shown to have an effect on the health target. This molecule is termed a “lead compound”. 124 
Databases which compile active compounds having previously been reported for specific targets 125 
are publicly available (Table 2). The utilisation of specific queries (i.e., structural similarities 126 
between compounds, suitable compounds which may interact with a specific target, etc.) has 127 
been described using different workflows (process automation, management, analysis and 128 
retrieval of data). The workflows used to design new drugs may be constructed and visualised 129 
using publicly available software such as Pipeline Pilot, KNIME and Taverna. The Open 130 
Pharmacological Concepts Triple Store (Open PHACTS) Discovery Platform 131 
(http://www.openphacts.org) has combined several publicly available databases for drugs, 132 
targets, pathways and diseases (for review, see: Chichester et al., 2015). Similarly, for dietary 133 
peptides, several publicly available databases (e.g., BIOPEP, PepBank, etc.) comprise BAP 134 
sequences (Table 3) previously reported for various bioactivities (e.g., antimicrobial, anticancer 135 
along with ACE and DPP-IV inhibitory properties). Specific databases have compiled BAPs 136 
originating from specific organisms (plants, snails, ruminants, etc.). In addition, a number of 137 
metabases such as MetaComBio (http://www.uwm.edu.pl/metachemibio/index.php/about-138 
metacombio) and OMICtools (http://omictools.com/) are available online. These allow the 139 
combination of several omic tools as well as information comprised in several other databases 140 
related to the bioactivity, safety and efficacy of compounds, making searches and data analysis 141 
more comprehensive. 142 
Other strategies may be used to identify the target peptides. Different proteomic and peptidomic 143 
tools for the analysis of dietary BAPs have been described in the recent review of Iwaniak, 144 
Minkiewicz, Darewicz, Protasiewicz, and Mogut (2015). Milk protein sequences can be accessed 145 
from online databases such as UniProtKB/Swiss-Prot (http://www.uniprot.org/uniprot/). In silico 146 
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(software-based) methods may be used to elucidate milk protein-derived peptide candidates for 147 
further in vitro testing (Dziuba & Dziuba, 2014). While a specific protein substrate may be 148 
indicated as a rich source of BAPs, it is necessary to subsequently identify enzymatic hydrolysis 149 
strategies to optimally release these peptides (Dziuba, Dziuba, & Iwaniak, 2009). One common 150 
use of in silico methods is the utilisation of peptide cutter programs which are available from a 151 
wide range of online proteomic tools, e.g., ExPASy, BIOPEP, MEROPS, MS-Digest (Protein 152 
Prospector), PROSPER, etc. A list of online peptide cutters is available from BIOPEP at the 153 
following link: http://www.uwm.edu.pl/biochemia/index.php/pl/biopep/42-proteolysis. Peptide 154 
cutters have been designed to predict the cleavage of primary protein structures using enzymes of 155 
known specificity. In reality, proteins generally also possess a secondary, tertiary and possibly a 156 
quaternary structure. This is the case particularly for native whey proteins (WPs). For instance, 157 
native -lactoglobulin (-Lg) and -lactalbumin (-La) comprise 2 and 4 disulfide bonds, 158 
respectively. The secondary, tertiary and quaternary structures may affect the ability of in silico 159 
tools to predict cleavage sites of native proteins. 160 
In other instances, the selected peptides may be chosen based on their physicochemical 161 
properties (e.g., molecular mass and hydrophobicity). Various peptide calculators allow an 162 
estimation of diverse physicochemical properties of peptides. Examples of such software can be 163 
found at the following BIOPEP link: http://www.uwm.edu.pl/biochemia/index.php/pl/biopep/38-164 
physico-chemical-properties. In the context of milk protein-derived BAPs, it may be useful to 165 
design a “milk protein database” (Le Maux, Nongonierma, & FitzGerald, 2015) in order to 166 
restrict the search space for candidate peptides. 167 
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5 Screening of potential peptide candidates for a given health target 168 
The next step following the selection of peptide candidates is bioactivity screening of the 169 
peptides (Fig. 1). Peptide screening may be conducted in various ways, using in silico, in vitro 170 
bioassays or directly using animal models (ex vivo, in situ and in vivo experiments) or human 171 
subjects. A systematic approach whereby BAPs may be sequentially evaluated using all four 172 
screening modes (i.e., in silico, in vitro, ex vivo/in situ and in vivo) can be utilised. In theory, the 173 
number of potential peptides should be reduced at each stage of the screening process. In 174 
general, prior screening is conducted because in vivo testing may be relatively time consuming, 175 
costly and requires ethical approval (Foltz, van der Pijl, & Duchateau, 2010). 176 
5.1 In silico screening 177 
In silico screening may be applied to milk BAPs to (a) predict their biological activity, (b) study 178 
their mechanism of action or (c) establish relationships between physicochemical parameters and 179 
bioactive properties. Chemometric approaches such as quantitative structure activity relationship 180 
(QSAR), artificial neural networks (ANN) and virtual screening have recently been reviewed 181 
(Iwaniak et al., 2015). ANNs, which are based on machine learning algorithms, have been used 182 
in certain instances to aid in the discovery of novel milk BAPs such as antimicrobial peptides 183 
(AMPs) (Dziuba & Dziuba, 2014). Other in silico methods such as molecular docking and 184 
QSAR will be described in the following paragraphs. 185 
Molecular docking, is a computational method which predicts peptide binding to specific sites 186 
(e.g., receptors and active sites of enzymes) of proteins and quantitatively assesses binding 187 
energy using a scoring system (Pripp & Ardö, 2007). In the context of milk protein-derived 188 
BAPs, most studies appear to have been conducted with ACE inhibitory peptides (Norris, Casey, 189 
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FitzGerald, Shields, & Mooney, 2012; Pan, Cao, Guo, & Zhao, 2012). Two novel ACE 190 
inhibitory peptides, Asp-Trp and Trp-Pro, were identified using molecular docking (Norris et al., 191 
2012). Molecular docking has shown that binding of Leu-Leu, a whey protein-derived peptide, to 192 
ACE involved hydrophobic interactions and also interaction with Zn
2+
, a cofactor for ACE 193 
inhibition (Pan et al., 2012). Some examples are also found with DPP-IV and xanthine oxidase 194 
(XO) inhibitory peptides (Nongonierma, Mooney, Shields, & FitzGerald, 2013; Nongonierma, 195 
Mooney, Shields, & FitzGerald, 2014). In order to conduct meaningful molecular docking, prior 196 
knowledge of the site of interaction of the peptides (discrimination between competitive and 197 
non-competitive DPP-IV inhibitors) is highly relevant (Nongonierma et al., 2014). This is 198 
because molecular docking assumes binding of BAPs to specific sites, e.g., the active site of key 199 
metabolic enzymes. 200 
QSAR is based on a mathematical model linking structural characteristics of molecules to their 201 
biological properties (for reviews, see: Jenssen, 2011; Pripp, Isaksson, Stepaniak, Sørhaug, & 202 
Ardö, 2005). Scalar descriptors for amino acids have been developed for QSAR analysis 203 
(Hellberg, Sjöeströem, Skagerberg, & Wold, 1987; Tian et al., 2015). Target peptides are 204 
described with a multivariate approach using their amino acid descriptors. A mathematical model 205 
linking the structural characteristics (peptide descriptors - independent variables) to biological 206 
activity (dependent variable) is then built based on computational methods (e.g., partial least 207 
square regression (PLSR), multiple linear regression (MLR), principal component analysis 208 
(PCA) or ANN) (Jahangiri, Soltani, & Barzegar, 2014). When the biological activity data is 209 
taken from different sources, care must be taken to select data which was obtained in 210 
experimental conditions which are as similar as possible (Pripp et al., 2005). QSAR studies have 211 
been carried out with milk protein-derived peptides (Jing et al., 2014; Pripp, Isaksson, Stepaniak, 212 
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& Sørhaug, 2004; Wu, Aluko, & Nakai, 2006a, 2006b). The QSAR approaches used for the 213 
analysis of ACE inhibitory peptides have been recently reviewed (Jahangiri et al., 2014). Di- and 214 
tripeptides with large bulky and hydrophobic amino acids (i.e., Trp, Tyr and Phe) at the C- and 215 
N-terminus or a Pro at the C-terminus and branched aliphatic side amino acids at the N-terminus 216 
were predicted to be potent ACE inhibitory peptides. For peptides > 3 amino acids, potent ACE 217 
inhibitors were shown to generally possess bulky and hydrophobic C-terminal amino acids and 218 
the N-terminal amino acid had a lower influence on ACE inhibition (Pripp et al., 2004; Wu et al., 219 
2006b). QSAR approaches allowed identification of milk protein-derived peptides with similar 220 
(Ile-Val-Pro (s1-CN (f 86-88)) and Val-Ile-Pro (s2-CN (f 215-217))) (Jing et al., 2014) or lower 221 
(Tyr-Phe (-La (f 122-123)) and Leu-Arg-Phe (s1-CN (f 36-38))) (Wu et al., 2006a) ACE half 222 
maximal inhibitory concentration (IC50) values compared to Ile-Pro-Pro. 223 
QSAR has also been used for the study of AMPs (for review, see Jenssen, 2011). A number of 224 
QSAR analyses with milk AMPs have been carried out (Nakai, Chan, Li-Chan, Dou, & Ogawa, 225 
2003; Strøm, Stensen, Svendsen, & Rekdal, 2001). These have attempted to identify novel 226 
analogs of lactoferricin (LFcin), a well-known AMP derived from lactoferrin (LF). Murine LFcin 227 
analogs have been studied by QSAR for their antimicrobial activity, which has allowed 228 
prediction of the antimicrobial activity of a bovine LFcin derivative, LF (f 17-31) (Strøm et al., 229 
2001). The parameters which correlated with the antimicrobial activity were shown to be the -230 
helix forming-propensity of positions 4-9 of LFcin (Nakai et al., 2003), the cationic charge and 231 
micelle affinity of the peptides (Strøm et al., 2001). 232 
Other QSAR studies have found application in the discovery of antioxidant peptides. The 233 
characteristics of both the C- (hydrophilicity, hydrogen bond and electronic properties) and N-234 
terminal (hydrophobicity and electronic properties) amino acids correlated with the antioxidant 235 
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activity of tri- and tetrapeptides (Li, Li, He, & Qian, 2011). The electronic properties of peptides 236 
were shown to play the most important role in the radical scavenging activity, along with the 237 
presence of a bulky hydrophobic amino acid at the C-terminus of peptides (Li & Li, 2013). A 238 
systematic evaluation of the antioxidant capacity (ferric reducing antioxidant power - FRAP) of 239 
all possible tripeptides (172 unique sequences) from -Lg was carried out (Tian, Yang, Lv, 240 
Yang, & Zhou, 2009). Cys- and Trp-containing tripeptides were associated with high antioxidant 241 
activity. The effect of both amino acid residues has been explained by their ability to interact 242 
with free radicals through hydrogen (-SH and indole group), electron (S) or proton (aromatic ring 243 
of Trp) donation. It was found that 3 -Lg tripeptides (Leu-Thr-Cys, Cys-Gln-Cys and Gly-Thr-244 
Trp) had a higher antioxidant activity than the well-known physiological antioxidant gluthatione 245 
(Glu-Cys-Gly). 246 
To date several in silico studies with milk BAPs have been reported in the literature. However, 247 
only a few of these studies have been validated with additional analyses. Several examples of 248 
studies combining in silico, being used as a predictive tool for the enzymatic release of potent 249 
milk BAPs, and in vitro studies exist for antioxidant (Nongonierma & FitzGerald, 2012b), ACE 250 
(Norris et al., 2012; Norris, Poyarkov, O’Keeffe, & FitzGerald, 2014; Wang, Zhang, Wang, 251 
Feng, & Shan, 2011) and DPP-IV (Nongonierma & FitzGerald, 2013; Tulipano, Faggi, Nardone, 252 
Cocchi, & Caroli, 2015) inhibitory peptides. In general, there was a good agreement between in 253 
silico prediction and the in vitro bioactive properties of the resultant hydrolysates. In the study of 254 
Tulipano et al. (2015), -Lg was predicted to yield a higher number of DPP-IV inhibitory 255 
peptides following in silico GI digestion than -La. This was verified in vitro with DPP-IV IC50 256 
values of 0.74 and 1.7 mg mL
-1
 for -Lg and -La, respectively. Many studies have identified 257 
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peptides within hydrolysate fractions and subsequently synthesised them to evaluate their 258 
activity in vivo (Kaiser et al., 2016; Nakamura, Yamamoto, Sakai, & Takano, 1995; Sánchez-259 
Rivera et al.; Sawada et al., 2015; Uenishi, Kabuki, Seto, Serizawa, & Nakajima, 2012; Yamada 260 
et al., 2015). Limited studies are available on in silico predictions of milk BAPs which have 261 
further been validated in vivo. Such a study has been reported for CN-derived peptides, Ile-Val-262 
Pro (αs1-CN (f 71-73) and αs1-CN (f 111-113)) and Val-Ile-Pro (αs2-CN (f 200-202)), which have 263 
been predicted by QSAR to inhibit ACE. When evaluated in rats, these peptides induced a 264 
reduction in SBP (Jing et al., 2014). 265 
5.2  In vitro screening 266 
Different in vitro bioassays, which are similar in nature to those employed in pharmaceutical 267 
screening, can be found for a wide range of milk BAP targets as outlined in Table 2. The in vitro 268 
tests described for assessing milk protein BAPs may be classified into chemical, enzymatic or 269 
cell culture tests. For example, the most current in vitro and in vivo methods used to assess the 270 
antioxidant potential of dietary peptides have been summarised in a recent review by de Castro 271 
and Sato (2015). 272 
The correlation between in vitro bioassays and in vivo data obtained with dietary BAPs has often 273 
been questioned (Foltz et al., 2010). The reason for the lack of agreement between in vitro 274 
bioassays and in vivo outcomes may be due to the low bioavailability and stability of BAPs in 275 
animals and humans. Foltz et al. (2010) proposed testing of BAPs in concentrations and time 276 
frames which are physiologically relevant. This is particularly pertinent since it was shown, for 277 
example, that the enzyme concentration used in in vitro bioassays could affect the level of 278 
bioactivity measured (Murray, Walsh, & FitzGerald, 2004). In addition, the origin of the 279 
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biological material also matters. Different extents of in vitro DPP-IV inhibition were obtained 280 
with peptides incubated with porcine or recombinant human DPP-IV, possibly due to regions in 281 
the catalytic site of DPP-IV which are not conserved among species (Lacroix & Li-Chan, 2015). 282 
5.3 Ex vivo and in situ screening 283 
Biological fluids (e.g., blood, serum or plasma) may be used to study milk protein BAPs. For 284 
example, structural similarities exist between fibrinogen and bovine caseinomacropeptide (CMP, 285 
-CN (f 106-169)). Cow’s CMP and associated peptide fragments (Lys-Asn-Gln-Asp-Lys and 286 
Met-Ala-Ile-Pro-Pro-Lys-Lys-Asn-Gln-Asp-Lys) have been evaluated for their antithrombic 287 
activity. CMP (5 mg kg
-1
), peptide fragments from CMP (i.e., Lys-Asn-Gln-Asp-Lys (5 mg kg
-1
), 288 
Met-Ala-Ile-Pro-Pro-Lys-Lys-Asn-Gln-Asp-Lys (10 mg kg
-1
)) were administered by intravenous 289 
(IV) injection to guinea pigs (Bal dit Sollier et al., 1996). No antithrombic effect could be seen 290 
when adenosine diphosphate (ADP)-induced platelet aggregation was evaluated ex-vivo using a 291 
turbidimetric approach. This was in contrast with the fact that these peptides displayed 292 
antithrombic activity in vivo, suggesting that different mechanisms of action may have been 293 
involved. 294 
Other ex-vivo methods have been based on the evaluation of milk BAPs on cells harvested from 295 
animal tissues. The capacity to secrete insulin was restored in the pancreatic cells of ob/ob mice 296 
treated (100 mg kg
-1
 for 8 weeks) with an insulinotropic WP hydrolysate (WPH) as compared to 297 
the control mice (29 ± 2 vs. 12 ± 2 fmol insulin L
-1
 islet
-1
, respectively) (Gaudel et al., 2013). 298 
The anti-inflammatory properties (down-regulation of pro-inflammatory cytokines following a 299 
lipopolysaccharide challenge) of an ultrafiltration (UF) fraction (5 kDa retentate and 1 kDa 300 
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retentate) of a sodium caseinate hydrolysate were demonstrated ex vivo using porcine colonic 301 
tissue (Mukhopadhya et al., 2015). 302 
The use of ex vivo protocols has been widely described for the evaluation of CPP related 303 
anticariogenic and mineralising properties (for reviews, see: Lenton, Nylander, Teixeira, & Holt, 304 
2015; Nongonierma & FitzGerald, 2012a). Increased Ca absorption has been reported in the 305 
presence of CPPs in ligated rat ileum segments (Lee, Noguchi, & Naito, 1983; Sato, Noguchi, & 306 
Naito, 1986), everted gut sacs and duodenal loops of chicks (Mykkanen & Wasserman, 1980) 307 
and rat duodenal loops (Pérès et al., 1999). Ca absorption in the presence of CPPs in everted rat 308 
ilea was studied and it was shown to depend on the Ca:Pi (Erba, Ciappellano, & Testolin, 2001) 309 
as well as CPP:Ca ratio (Erba, Ciappellano, & Testolin, 2002). The instability of β-CN (f 1-25)-310 
Fe was shown to involve the action of peptidases/proteinases and also phosphatase activities in 311 
rat duodenal loops (Bouhallab et al., 1999). 312 
Other protocols which are classified as in situ have also been used to study the remineralising 313 
properties of CPPs with dental appliances placed directly in the oral cavity of humans 314 
(Ferrazzano, Amato, Cantile, Sangianantoni, & Ingenito, 2011). 315 
The hypotensive activity of milk protein-derived peptides has been evaluated by determination of 316 
their effect on contractile capacity of the arteries of small animals following stimulation with 317 
angiotensin-I ex vivo. LF-derived peptides (Fernández-Musoles et al., 2014; Ruiz-Giménez et al., 318 
2010), a LF hydrolysate (Ruiz-Giménez et al., 2007) and a 3 kDa UF permeate of a LF 319 
hydrolysate (Fernández-Musoles et al., 2014) were shown to reduce angiotensin-I dependent 320 
carotid artery contraction ex-vivo in rabbits. Similarly, Met-Lys-Pro (s2-CN (f 190–192)) 321 
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reduced angiotensin-I induced vasoconstriction on thoracic aorta from spontaneous hypertensive 322 
rats (SHRs) (Yamada et al., 2015). 323 
5.4 Bioavailability and safety evaluations 324 
The toxicity and bioavailability is generally evaluated following screening of the target 325 
compounds (Fig. 1). The toxicity may be evaluated in cell cultures, invertebrates or small 326 
animals using cell viability assays and determination of lethal dose 50 (LD50) (for review, see: 327 
Doke & Dhawale, 2015). Different cytotoxicity assays of natural compounds which allow 328 
assessment of (a) metabolism (e.g., 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 329 
bromide (MTT) and 3-(4, 5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenyl)-2-(4-330 
sulfophenyl)-2H-tetrazolium, inner salt (MTS)), (b) membrane integrity (e.g., lactate 331 
dehydrogenase (LDH), fluorescent staining), (c) oxidative damage (e.g., fluorescent probes) and 332 
(d) deoxyribonucleic acid (DNA) damage (e.g., Comet assays) have recently been reviewed 333 
(Bunel, Ouedraogo, Nguyen, Stévigny, & Duez, 2014). 334 
Since milk protein-derived BAPs are natural components which are released during GI digestion, 335 
they are generally considered as safe for human consumption. A number of studies have 336 
evaluated the cytotoxicity of specific milk BAPs. In vitro cytotoxicity (rat fibroblasts) of a 337 
commercial CPP-ACP paste (Tooth Mousse
TM
) was conducted (Bussadori et al., 2010). A low 338 
cytotoxicity was seen after 4 h to 7 days exposure, resulting in < 30% decrease in cell viability 339 
(L929 fibroblast), which was linked with the additives present in Tooth Mousse
TM
 rather than 340 
CPP-ACP (Cehreli, Gurpinar, Onur, & Dagli, 2008). The LTPs, Ile-Pro-Pro and Val-Pro-Pro, 341 
were evaluated as safe in cell cultures and in small animal studies (for review, see: Phelan, 342 
Aherne, FitzGerald, & O'Brien, 2009). Human studies have shown that the AMP, LF (f 1-11), 343 
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was not associated with cytotoxic effects (Brouwer, Rahman, & Welling, 2011; van der Velden, 344 
van Iersel, Blijlevens, & Donnelly, 2009). 345 
Bioavailability assessment is crucial in order to understand if the peptide has potential to (a) 346 
survive in the gastrointestinal tract (GIT), (b) permeate through the intestinal epithelium (c) 347 
remain stable in the circulation and (d) reach the target tissue(s)/organ(s). Earlier studies have 348 
estimated that significant amounts of BAPs were present in the GIT of humans. The different 349 
milk protein derived peptides which have been identified in the digestates of humans following 350 
milk or dairy food intake (Boutrou et al., 2013; Chabance et al., 1998; Meisel et al., 2003; 351 
Svedberg, de Haas, Leimenstoll, Paul, & Teschemacher, 1985) are summarised in Table 4. 352 
Interestingly, these peptides, which range from 4 (Tyr-Pro-Phe-Pro, -CN (f 60-63), bovine -353 
casomorphin-4) to 64 (CMP) amino acids in length, appear to originate mainly from -CN. For 354 
example, it was estimated that for 250 g of ingested milk, 120 mg CPPs were potentially present 355 
in the ileum (Meisel et al., 2003). A concentration of 600 µM CMP was found in jejunal contents 356 
after whey ingestion, vs. 45 and 5 µM following CN and yoghurt intake, respectively (Ledoux et 357 
al., 1999). While concentrations of 17 µM -casomorphin-7 (-CN (f60-66)) and 900 µM -CN 358 
(f108-113), an opioid and ACE inhibitory peptide, respectively, were found in the jejunum 359 
(Boutrou et al., 2013). However, the ability of dietary peptides to reach the circulation from 360 
humans in sufficient amounts to display bioactivity is still a subject of much debate (for review: 361 
see Miner-Williams, Stevens, & Moughan, 2014). 362 
In order to gain more relevant in vitro data, it is common practice to utilise simulated gastro-363 
intestinal digestion (SGID) procedures to assess the stability of BAPs to further digestion by GI 364 
enzymes (Raikos & Dassios, 2014; Stuknytė, Cattaneo, Masotti, & De Noni, 2015; Walsh et al., 365 
2004). Specific regions of milk proteins have been shown to be relatively resistant to GI enzyme 366 
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hydrolytic activities. These include the allergenic peptide β-Lg (f 125–135), phosphorylated 367 
CPPs (s1-CN (f 104-119) and -CN (f 26-41)) and hydrophobic regions of CNs (β-CN (f 76–368 
93), αs2-CN (f 36–75) and κ-CN (f 106–169)) (Picariello et al., 2010). The particular resistance 369 
of CPPs to SGID has been linked with their high level of phosphorylation (Vegarud, Langsrud, 370 
& Svenning, 2000). The stability of -casomorphins (3, 4, 5, 6 and 7) during SGID of cheese 371 
samples was studied (De Noni, Stuknytė, & Cattaneo, 2015). Only -casomorphin 4 and 7 could 372 
be detected following the SGID of different cheese samples. Based on this SGID study, it was 373 
estimated that following consumption of 30 g cheese between 0.02-0.16 µmol L
-1
 of -374 
casomorphin 7 may be released in jejunal effluents in humans, which was deemed too low to be 375 
compatible with modification of opioid activity in vivo. Foltz, Van Buren, Klaffke & Duchateau 376 
(2009a) designed a model to predict the intestinal stability of dipeptides. This model was further 377 
validated using in vitro simulated digestion results for 228 synthetic dipeptides. It was reported 378 
that ~50% of the dipeptides evaluated were relatively stable to in vitro intestinal hydrolysis. 379 
Recently, the stability of the ACE inhibitory peptides (Ile-Pro-Pro and Leu-Lys-Pro (-Lg (f 46-380 
48) and bovine serum albumin (BSA) (f 121-123)) to rat GI and liver homogenates has been 381 
demonstrated (Gleeson, Heade, Ryan, & Brayden, 2015). 382 
Other protocols to evaluate the bioavailability of milk BAPs are based on measurement of their 383 
permeability through Caco-2 cell monolayers, an in vitro model of the intestinal epithelium. 384 
Several studies have reported that milk BAPs were degraded by brush border peptidases during 385 
intestinal permeation (Miner-Williams et al., 2014; Picariello et al., 2013; Shimizu, Tsunogai, & 386 
Arai, 1997). However, permeation of intact peptides could be measured in the apical 387 
 19 
 
compartment as was the case for β-CN (f 193–209) (Regazzo et al., 2010) and β-Lg (f 127-135) 388 
(Picariello et al., 2013). 389 
The stability of milk BAPs to serum peptidases, which is particularly relevant to peptides with a 390 
systemic target, has also been investigated. The ACE inhibitory peptide β-Lg (f 142-148) was 391 
degraded upon incubation with human blood serum (Walsh et al., 2004). Another study showed 392 
that the ACE inhibitory milk protein-derived dipeptides (Val-Phe and Val-Tyr) were not 393 
degraded, while 10% degradation was observed for Ala-Trp following 30 min incubation with 394 
human blood serum (Pentzien & Meisel, 2008). 395 
In summary, as milk BAPs are naturally found in the GIT of humans, there is no major concern 396 
in terms of their safety. Measurement of milk peptide bioavailability has mainly been assessed 397 
using in vitro models. To date it is not clear how this body of information may be related to 398 
peptide bioavailability in humans. The main concern of using in vitro models to assess BAP 399 
bioavailability is that they may be too simplistic and not sufficiently integrative to mimic the 400 
human body. Ideally, assessment of peptide bioavailability should be carried out in vivo to 401 
generate more meaningful data. 402 
5.5 In vivo screening 403 
Evaluation of active substances in small animals and in humans is essential to validate their 404 
biological activity (Fig. 1). Different animal models which are relevant to study components of 405 
the MetS have been described in the scientific literature (for reviews, see: Aydin et al., 2014; 406 
Nelson & Reusch, 2014). Many of these animal models, which are genetically modified or are 407 
mutants, are commercially available. In addition, animal models may be developed in-house, for 408 
example, by subjecting healthy animals to food excess (models of obesity), allergens (models of 409 
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cow’s milk protein allergenicity) or harmful chemicals (e.g., trinotrobenzene sulfonic acid 410 
(TNBS)-colitis model of irritable bowel syndrome). Other animal models comprising negative or 411 
orphan models may also be utilised (for review, see: Hau, 2008). 412 
Milk protein-derived BAPs have been shown in animal studies to display significant effects on a 413 
wide range of outcomes such as BP reduction, immune modulation, mineral binding, 414 
antidiabetic, anticancer and hypocholesterolemic effects (for reviews, see: Hernández-Ledesma 415 
et al., 2014; Nongonierma & FitzGerald, 2012a; Raikos & Dassios, 2014). The bioavailability of 416 
milk peptides has been demonstrated both in animal and human studies. Ile-Pro-Pro, has been 417 
identified in the hepatic, renal, adrenal and aortic tissues of rat when administered at doses of 7 418 
mg kg
-1 
(Jauhiainen et al., 2007). Relatively low concentrations of LTPs (~ 1-10 nmol L
-1
) have 419 
been reported in the serum of piglets (van der Pijl, Kies, Ten Have, Duchateau, & Deutz, 2008) 420 
and humans (Foltz et al., 2007). This was linked to a relatively low bioavailability of 0.1% (Ile-421 
Pro-Pro, Val-Pro-Pro and Leu-Pro-Pro (-CN (f 151-153) and BSA (f 307-309))) found in 422 
piglets along with a relatively short half-life of absorption (5 min) and elimination (10 min) (van 423 
der Pijl et al., 2008). A similar study was conducted with the ACE inhibitory peptide His-Leu-424 
Pro-Leu-Pro (β-CN (f 134-138)), also revealing a low oral bioavailability of 5.18% in rat 425 
(Sánchez-Rivera et al., 2014). Recently, Yamada et al. (2015) have also shown that Met-Lys-Pro 426 
(s2-CN (f 190-192)) had a low bioavailability in rat, with a highest concentration of 0.90 µM 427 
detected in the plasma. Overall, the general low bioavailability of milk BAPs has raised 428 
questions about their role in the observed in vivo hypotensive effects. Therefore, it has been 429 
suggested that the bioactive properties of the LTPs may involve mechanisms of action other than 430 
ACE inhibition, e.g., interactions with gut receptors. In addition, accumulation of Ile-Pro-Pro and 431 
Val-Pro-Pro in various tissues (liver, kidney, lung and aorta) of SHR has been reported. Peptide 432 
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concentrations (> 10 µM), which are lower than the ACE IC50 values, were reported in the aortic 433 
tissue (Kawaguchi, Nakamura, Kamiie, Takahashi, & Yamamoto, 2012), which may be linked 434 
with their bioactive properties. A recent study conducted with pigs has demonstrated the 435 
increased bioavailability of Ile-Pro-Pro ( 4.7), Val-Pro-Pro ( 121) and Leu-Pro-Pro ( 2.5) 436 
when co-ingested with milk protein hydrolysates or meals. The increased bioavailability in the 437 
presence of other food components may be due to a slower rate of gastric emptying as well as 438 
prolonged elimination and differential organ metabolism (Ten Have, van der Pijl, Kies, & Deutz, 439 
2015). 440 
Screening of compounds in humans generally involve pilot trials which allow collection of data 441 
in relatively small groups of human subjects (Townsend, McFadden, Ford, & Cadée, 2004). 442 
While pilot trials may give some indications for the set-up of longer term human intervention 443 
studies (e.g., dosage, duration, etc.), they are generally statistically underpowered, often 444 
rendering data interpretation challenging. The different screening approaches described are 445 
complementary and they may help to better predict the biological properties of milk protein-446 
derived BAPs in humans. 447 
6 Human intervention studies 448 
Human trials are conducted following screening and identification of potentially active 449 
components (Fig. 1). However, it must be noted that a relatively poor correlation between animal 450 
and human study outcomes has been reported. It was stated that only ~ 1/3 of highly cited animal 451 
research outcomes with pharmaceutical compounds were in agreement with human randomised 452 
trials (Hackam & Redelmeier, 2006). The lack of agreement between animal and human studies 453 
has been attributed to biological differences between both groups (i.e., interindividual 454 
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differences, sex and aetiology of the disease) and differences in experimental set-up (study 455 
design, dose, timing, duration, etc.). It has therefore been recommended to design animal and 456 
human studies in conditions which are as similar as possible to allow direct comparison between 457 
both (McGonigle & Ruggeri, 2014). Furthermore, recommendations for conducting a systematic 458 
review and meta-analysis before embarking on a human intervention study have been made in 459 
order to design the study in a more informed fashion. 460 
Evaluation of milk BAPs in humans have been conducted mainly for their hypotensive, mineral 461 
binding, antidiabetic, satiating and cognitive properties. In addition, several meta-analyses 462 
evaluating the potential of milk BAPs for their hypotensive and anticariogenic properties are 463 
available in the scientific literature. Numerous meta-analyses have suggested a positive effect of 464 
milk protein-derived BAP ingestion on certain health outcomes in humans, i.e., BP reduction and 465 
teeth remineralisation. However, contradictory results have also been reported, with no 466 
modification in the health status of humans following the consumption of milk BAPs (for 467 
review, see: Nongonierma & FitzGerald, 2015c). 468 
 469 
To date, definite scientific evidence for the role of specific milk BAPs in human health would 470 
not appear to have been unequivocally established. Several reasons have been proposed for the 471 
contradictory results seen in human trials conducted with milk BAPs. These include (a) the lack 472 
of characterisation of the bioactive components within complex milk protein hydrolysates (b) the 473 
lack of knowledge on the mechanisms of action involved (c) low in vivo bioavailability/stability 474 
and potency of the milk BAPs (d) large interindividual differences between human subjects (e.g., 475 
genetic, racial, health status differences, etc.) (e) methodological issues (e.g., underpowered 476 
human intervention trials, non-relevant controls, inadequate blinding, timing of the intervention, 477 
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food matrix effects, etc.) (Nongonierma & FitzGerald, 2015c). In addition, few attempts to 478 
accurately quantify the amounts of peptides detected in humans have been carried out (Boutrou 479 
et al., 2013; Meisel et al., 2003). It is therefore challenging to understand whether these peptides 480 
have a biological relevance to human health or not. The current difficulty with specific human 481 
studies evaluating BAPs arises from the fact that they are generally aimed at systemic targets 482 
(e.g., ACE, renin, bones, brain, etc.). However, several targets are present in the oral cavity (e.g., 483 
teeth) or in the GIT (e.g., ACE, DPP-IV, microorganisms, selected immune cells, etc.) and may 484 
have potential to be positively modulated by milk BAPs.  485 
A major issue, which is also encountered with human intervention studies carried out with 486 
pharmaceutical drugs, is related with non-responder subjects. The putative role of genetic and 487 
racial variations has been suggested in meta-analyses conducted on the hypotensive LTPs 488 
(Cicero, Gerocarni, Laghi, & Borghi, 2011). It has been attempted to understand the factors 489 
which differed between responder vs. non-responder (systolic blood pressure (SBP) reduction < 490 
5 mmHg throughout the 8 week intervention) human subjects to hypotensive milk components. 491 
However, no significant differences in the parameters evaluated (i.e., age, body mass index, 492 
gender, heart rate and parameters of the renin-angiotensin-aldosterone system) could be 493 
identified (Usinger, Jensen, Flambard, Linneberg, & Ibsen, 2010). Such results pose challenges 494 
to analysis of the data. 495 
Recommendations have been made for the setup of human intervention studies targeting 496 
probiotic effects. These are also in line with the guidelines to conduct more targeted/efficient 497 
human intervention studies with milk BAPs. They consist in setting clear objectives in terms of 498 
the biological outcomes to be measured (targets and extent of the response) and establish a better 499 
selection of the population based on genetic markers or biological characteristics such as 500 
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surrogate markers of diseases (Reid et al., 2010). Gene expression-based methodologies may be 501 
used to accurately identify non-responder human subjects or subjects who have a predisposition 502 
to hypertension and other co-morbidities associated with the MetS (Siffert, 2005; Thomson et al., 503 
2015). In addition, the gut microbiota has been proposed to play a role in human health and in 504 
the responsiveness to nutritional interventions (Doré & Blottière, 2015; West et al., 2015). For 505 
the first time, intestinal microbial biomarkers have been identified to explain the differences in 506 
dietary responses of obese human subjects (Korpela et al., 2014). In this study, it was suggested 507 
that changes in the microbiota (more particularly that of Clostridium species) were seen because 508 
specific strains were sensitive to modifications in the intestinal environment. For example, the 509 
abundance of Clostridium sphenoides increased with a reduction in blood cholesterol level. 510 
7 Other aspects in milk BAP development 511 
Several other aspects need to be taken into account when studying milk protein-derived BAPs 512 
such as the novelty of the peptide sequence being evaluated. Several databases of dietary BAPs 513 
are available publicly (Table 3). These databases are not exhaustive and sometimes additional 514 
sources of information may be available in the patent literature. To our knowledge, there is no 515 
such database which captures the information available in the patent literature in the format of an 516 
open access database. While this information is not peer-reviewed, it could still be very relevant 517 
to inform researchers in the selection of the BAP sequences for further studies. This is also very 518 
relevant for food companies putting significant efforts into developing proprietary food protein 519 
hydrolysates. 520 
The production yield for BAPs is also an important parameter. The targeted design of 521 
experiments has been applied to optimally release milk BAPs during enzymatic hydrolysis. A 522 
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number of examples are found for ACE inhibitory (Naik, Mann, Bajaj, Sangwan, & Sharma, 523 
2013; van der Ven, Gruppen, de Bont, & Voragen, 2002) and antioxidant peptides (Contreras, 524 
Hernández-Ledesma, Amigo, Martín-Álvarez, & Recio, 2011a; Naik et al., 2013). The 525 
optimisation of hydrolysis parameters involves the design of a multifactorial model in which 526 
independent parameters are processing parameters (i.e., substrate pretreatment, temperature, pH, 527 
enzyme to substrate ratio, time, etc.) and the dependent variables are the bioactive outcomes and 528 
physicochemical properties of the hydrolysates. This approach provides a systematic 529 
methodology to produce milk protein hydrolysates with enhanced bioactive properties using a 530 
limited number of experiments. It also allows a better understanding of the processing 531 
parameters and their interactive effects which govern the release of the BAPs. 532 
Sensory defects are often reported with milk protein hydrolysates, bitterness notably being a 533 
major issue. It has been proposed that peptide bitterness is linked with their hydrophobicity as 534 
well as their size and structural characteristics such as the presence of Pro residues inside of the 535 
peptide sequence (for review, see: FitzGerald & O'Cuinn, 2006). Specific peptides linked with 536 
increased bitterness of milk protein hydrolysates have been identified. Sequences from bitter 537 
peptides may be found within BAP databases such as BIOPEP and Bitter DB (Wiener, Shudler, 538 
Levit, & Niv, 2012). Three peptides (Gly-Pro-Phe-Pro-Val-Ileu (unknown), Phe-Phe-Val-Ala-539 
Pro-Phe-Pro-Glu-Val-Phe-Gly-Lys (s1-CN (f 23-36)), Phe-Ala-Leu-Pro-Gln-Tyr-Leu-Lys (s2-540 
CN (f 174-181))) from a bitter tryptic CN hydrolysate were shown to be responsible for the 541 
bitterness (Matoba, Hayashi, & Hata, 1970). Similarly, a fragment released from -Lg by 542 
glutamyl endopeptidase activity, Val-Glu-Glu-Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu-Glu-Ile-543 
Leu (-Lg (f 43-57)), was shown to be implicated in the bitterness of a WP hydrolysate 544 
(Spellman, O’Cuinn, & FitzGerald, 2009). Four bitter peptides were identified in a WP 545 
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hydrolysate, Tyr-Gly-Leu-Phe (-La (f 50-53)), Ile-Pro-Ala-Val-Phe (-Lg (f 79-82)), Leu-Leu-546 
Phe (-Lg (f 103-105), LF (f 298-300) and LF (f 659-641)) and Tyr-Pro-Phe-Pro-Gly-Pro-Ile-547 
Pro-Asn (-CN (f 60-68)). These 4 peptides were shown to be responsible for 88% of the 548 
bitterness of the WP hydrolysate (Liu, Jiang, & Peterson, 2014). QSAR approaches have been 549 
used to better understand the characteristics of peptides which are responsible for bitterness 550 
attributes. It was shown that hydrophobic and bulky basic amino acids at the C- and N-terminal 551 
position of peptides (229 peptides of 2-14 amino acid residues in length evaluated) correlated 552 
with bitterness (Kim & Li-Chan, 2006). Wu and Aluko (2007) have shown using QSAR that the 553 
bitterness of di- and tripeptides increased when a bulky amino acid (e.g., Trp, Arg, Tyr) was 554 
adjacent to an hydrophobic amino acid at the C-terminal position of the peptide. Based on QSAR 555 
analysis, a positive correlation between selected bioactivities (e.g., ACE inhibition and 556 
antioxidant activity) of di- and tripeptides and their bitterness has been proposed (Pripp & Ardö, 557 
2007; Wang et al., 2013). For this reason, it was suggested that larger peptides may be beneficial 558 
for these bioactive properties while showing a lower bitterness profile (Pripp & Ardö, 2007).  559 
Debittering solutions comprise the selective utilisation of commercially available food-grade 560 
enzyme preparations, isoelectric precipitation, extraction with food-grade solvents, masking 561 
agents (i.e., flavours and sweeteners) and adsorption on chromatographic resins or activated 562 
carbon (for reviews, see: FitzGerald & O'Cuinn, 2006; Sun-Waterhouse & Wadhwa, 2013). 563 
Recently, an interesting review providing some relevant information on bitterness masking 564 
approaches used in the pharmaceutical and food industry has been compiled (Coupland & Hayes, 565 
2014). The bitterness of a tryptic -CN (a substrate particularly rich in Pro) hydrolysate has been 566 
shown to increase with the degree of hydrolysis (DH). Debittering of the -CN hydrolysate on 567 
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incubation with aminopeptidase activities (X-prolyldipeptidyl aminopeptidase (PepX) followed 568 
by leucine aminopeptidase (LAP)) has been reported (Barry, O'Cuinn, Harrington, O'Callaghan, 569 
& Fitzgerald, 2000). Processing parameters such as the level of total solids (TS) used during 570 
hydrolysis may also help to reduce bitterness. For the same DH, a significantly lower bitterness 571 
in WP hydrolysates could be achieved for hydrolysis carried out at 300 vs. 50 g TS L
-1
 572 
(Spellman, O'Cuinn, & FitzGerald, 2005). A linear correlation could be established between the 573 
amount of -Lg (f 43-57), which was present at higher concentrations in the hydrolysates at 574 
lower TS, and the bitterness of the hydrolysates. Recently, debittering of an ACE inhibitory WP 575 
hydrolysate has successfully been achieved by the utilisation of commercially available 576 
exopeptidases while maintaining its bioactivity (Cheung, Aluko, Cliff, & Li-Chan, 2015). In 577 
addition, encapsulation techniques may help to reduce the perceived bitterness and sensory 578 
defects of milk protein hydrolysates (for reviews, see: Celli, Ghanem, & Brooks, 2015; Đorđević 579 
et al., 2015). The encapsulation of milk protein hydrolysates has been described using spray-580 
drying (Ma et al., 2014; Subtil et al., 2014), coacervation (Mendanha et al., 2009), lipospheres 581 
(Morais et al., 2004; Pinho & da Silva, 2013) and liposomes (Morais et al., 2004). 582 
The stability of the peptides to different technological processes as well as storage should be 583 
evaluated (López-Fandiño, Otte, & van Camp, 2006). The stability of Ile-Pro-Pro and Val-Pro-584 
Pro within powdered Lactobacillus helveticus milk fermentates has been reported over 6 month 585 
storage at 20C (Maeno, Nakamura, Mennear, & Bernard, 2005). It was demonstrated for the 586 
ACE inhibitory peptides, Arg-Tyr-Leu-Gly-Tyr (s1-CN (f 90-94)) and Ala-Tyr-Phe-Tyr-Pro-587 
Glu-Leu (s1-CN (f 143-149)), that homogenisation, pasteurisation and atomisation did not 588 
modify their amounts in a CN hydrolysate. In addition, they were not degraded during storage at 589 
4C for 4 weeks in a yoghurt matrix (Contreras et al., 2011b). Modifications of the 590 
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physicochemical properties (glass transition temperature - Tg) of WP hydrolysates have been 591 
reported as a function of the relative humidity (RH) and storage temperature. The Tg decreased 592 
at higher RH and DH values (Zhou, Liu, Chen, Chen, & Labuza, 2014). A decrease in Tg is 593 
detrimental to the matrix stability since at storage temperatures > Tg, modifications in the 594 
microstructure (state changes from glass to rubber) occur. No modification in the peptide profile 595 
of the hydrolysates could be seen under different storage conditions after 2 weeks. The thermal 596 
and pH denaturation of WP prior to enzymatic hydrolysis has been shown to affect the bioactive 597 
properties (Leeb, Götz, Letzel, Cheison, & Kulozik, 2015; O'Loughlin, Murray, FitzGerald, 598 
Brodkorb, & Kelly, 2014). 599 
The last step of the drug discovery workflow is regulatory approval of the newly developed 600 
molecule (Fig. 1). Milk BAPs have been evaluated by regulatory bodies such as the European 601 
Food Safety Authority (EFSA). To date, EFSA evaluations of milk BAPs have resulted in 602 
negative scientific opinions regarding their potential bioactive effects (hypotensive, 603 
remineralising and opioid) in humans. Several of these negative opinions have been attributed to 604 
a lack of cause-effect relationship between the BAPs and their presupposed health benefits for 605 
humans and also due to inconclusive human intervention data (Nongonierma & FitzGerald, 606 
2015c). To date, no milk protein hydrolysate claim has been approved by EFSA. In the US, the 607 
Food and Drug Administration (FDA) grants qualified health claims to products based on 608 
scientific evidence (Aryee & Boye, 2015). To date, no health claim has been attributed to milk 609 
protein hydrolysates by the FDA. In contrast, several milk protein BAPs have been granted 610 
health approval in Japan. These ingredients have been formulated in food classified as foods for 611 
specified health use (FOSHU). FOSHU with milk BAPs comprise hypotensive, mineral binding, 612 
antimicrobial, immunomodulatory and stress-reducing peptides (Shimizu & Hettiarachchy, 613 
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2012). Despite numerous studies conducted with milk BAPs, regulatory approval, particularly in 614 
the European Union, is still a major hurdle for developed health claims (Lalor & Wall, 2013). 615 
8 Concluding remarks and recommendations 616 
The workflow to study milk protein-derived BAPs using conventional drug discovery 617 
approaches has been outlined in this review. Drugs and dietary BAPs are in essence quite 618 
different in terms of (a) potency, (b) purity and (c) natural occurrence in vivo. Based on these 619 
differences, the main questions which have arisen during the preparation of this review are the 620 
following: “is it adequate to study milk BAPs using drug discovery methodology?” and “what 621 
are the alternative approaches?” 622 
To answer these questions, we believe that drug discovery approaches provide excellent 623 
methodological tools which have proven to be critical for the advancement of research in the 624 
field of dietary BAPs. However, it appears very clear that studying milk protein-derived BAPs 625 
taking a different approach to conventional drug discovery may be beneficial. It is evident that 626 
the complex composition of milk protein hydrolysates is a major issue. In fact most human 627 
intervention studies have been conducted with hydrolysates rather than with the isolated BAP 628 
sequence. This often makes it nearly impossible to understand where the bioactivity is coming 629 
from and how antagonistic/agonistic effects may influence the overall biological outcome. This 630 
suggests that new approaches need to be developed to maximise scientific outputs. In this 631 
context, it is worth considering reversing the workflow of the conventional drug discovery 632 
approach, starting from in vivo data and then going to in vitro testing (Fig. 1). This may help to 633 
improve the discovery of milk BAPs and to strengthen the likelihood of subsequently validating 634 
effects in humans. The low translation between in vitro and in vivo data is currently a major 635 
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hurdle in the development of milk BAPs with biological activity in humans. Foltz et al. (2010) 636 
proposed the design of research strategies which would better integrate knowledge of the 637 
behavior of BAPs in vivo (i.e., plasma concentrations and kinetics of absorption). They therefore 638 
suggested the relevance of studying peptides which are relatively stable to the hydrolytic activity 639 
of proteinases and peptidases as well as having physiologically relevant absorption, distribution, 640 
metabolism, and excretion (ADME) profiles. This would allow application of a preliminary 641 
“filter” to the peptide candidates to be tested in vitro. In addition, BAPs should be tested at 642 
concentrations as low as those found within biological fluids (pM vs. µM to mM in the 643 
conventional approach) and for shorter times (min vs. h in the conventional approach). 644 
While this in vivo to in vitro approach appears more relevant than the conventional approach 645 
currently in place for the discovery of dietary BAPs, serious limitations exist. There is a need to 646 
intensify research efforts in characterising milk peptides in humans post ingestion of milk and 647 
dairy products. Until recently, there was no such database summarising the sequences of peptides 648 
which have been identified either in the digestate or in the circulation of humans following the 649 
ingestion of intact or hydrolysed milk proteins. However, the information compiled in this 650 
review (Table 4) and in recent review articles (Boutrou, Henry, & Sanchez-Rivera, 2015; 651 
Nongonierma & FitzGerald, 2015c) may now be used as a starting point to design better 652 
informed studies. In addition, peptide sequences may be more easily identified in human samples 653 
with the development of liquid chromatography tandem mass spectrometric (LC-MS/MS) 654 
strategies such as those described for the identification of short peptides within complex milk 655 
protein hydrolysates (Le Maux et al., 2015). These short peptides are thought to be relatively 656 
resistant to the proteolytic action of proteinases and peptidases and they have also been 657 
associated with good bioavailability profiles (Foltz, van Buren, Klaffke, & Duchateau, 2009). 658 
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QSAR approaches have also been used to increase the level of understanding on the structural 659 
characteristics of the peptides which are linked with specific bioactivities and sensorial 660 
properties. QSAR has allowed the design and discovery of more potent BAPs. The production of 661 
milk protein hydrolysates enriched with these potent BAPs may be achieved through the 662 
utilisation of design of experiments combined with bioinformatic tools to predict optimum 663 
hydrolysis parameters which would yield enhanced enzymatic release of the BAPs. 664 
Carriers used in the pharmaceutical sector which are compatible with the protection and delivery 665 
of peptides and proteins as well as encapsulation strategies may help to enhance bioavailability 666 
of milk BAPs (Moutinho, Matos, Teixeira, & Balcão, 2012). It has been suggested that lipid-667 
based carriers (e.g., emulsions, liposomes, nanoemulsions, micelles and solid lipid particles) may 668 
be used as vectors for BAPs to increase their bioavailability in humans. To our knowledge, no 669 
study appears to have evaluated the impact of encapsulation of milk BAPs in humans. This gap 670 
in knowledge needs to be urgently addressed. Recently, an ex vivo animal study has 671 
demonstrated that in the presence of medium chain fatty acids (MCFA, i.e., sodium caprate and 672 
sodium salt of 10-undecylenic acid), it was possible to increase ACE inhibitory peptide (Ile-Pro-673 
Pro and Leu-Lys-Pro) permeation up to 3.6 and 14 fold in the jejunum and colon, respectively 674 
(Gleeson et al., 2015). It has been shown in animals that co-ingestion of ACE inhibitory milk 675 
BAPs and foods had a positive effect on in vivo hypotensive properties (Ten Have et al., 2015). 676 
An increase in the bioavailability may require an appropriate timing of the ingestion of milk 677 
BAPs and meal intake along with the utilisation of MCFA permeation enhancers. 678 
Another unexplored avenue is food-drug interactions. In vitro evidence exists, showing that 679 
Sitagliptin, an antidiabetic drug and milk BAPs in a mixture have additive or synergistic effects 680 
on DPP-IV inhibition (Nongonierma & FitzGerald, 2015d). Recently, interactive effects between 681 
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the hypotensive drug Enaprilat (3 mg kg
-1
) and the LTPs (3.5 mg kg
-1
), Ile-Pro-Pro and Val-Pro-682 
Pro, have been reported in hypertensive rats (Watanabe et al., 2015). The higher reduction in 683 
SBP seen with the sequential treatment of Enaprilat and LTPs compared to Enaprilat alone was 684 
only observed in the long-term study (6 weeks). In contrast, in the acute study a higher reduction 685 
in SBP was measured with the Enaprilat alone compared to the Enaprilat + LTP combination. 686 
This may have been linked to competitive effects at gut level for peptide absorption. It would be 687 
quite interesting to study the implications of these interactive effects in humans in order to 688 
understand if milk BAPs could be used in combination with therapeutic drugs to alleviate 689 
diseases in humans. 690 
Overall, there has been an increasing interest over the years for the discovery of milk BAPs. 691 
However, the investments of the food industry in this area have not been comparable to that of 692 
pharmaceutical sector in drug discovery. The costs associated with bringing a new molecular 693 
entity (NME) to the market have been estimated at $1.8 billion, with a drug discovery process 694 
and development which can take up to 13.5 years (Paul et al., 2010). There is no doubt that such 695 
a significant level of investment and time commitment in the discovery of BAPs would allow 696 
greater advances in the area. Finally, the integration of multidisciplinary skills may lead to 697 
improved discovery and production of milk BAPs. Good clinical practice must be taken into 698 
account for the design of robust human intervention studies. These include the best experimental 699 
set up (double blind randomised clinical trial, adequately statistically powered study, etc.) and 700 
careful selection of the cohort for the study based on their health/nutritional/genetic status. All 701 
the above recommendations aiming to (a) improve the rate of discovery of milk protein-derived 702 
BAPs and (b) set up scientifically validated human intervention studies are summarised in Fig. 2 703 
as a “take home message”. 704 
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Table 1. Examples of databases relative to targets used in drug discovery and clinical trial design 1147 
and outcomes. 1148 
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Table 2. Examples of targets and in vitro bioassays which have been described in the scientific 1150 
literature for evaluating milk protein-derived bioactive peptides (BAPs) 1151 
 1152 
Table 3. Publicly available databases for bioactive peptide sequences. Data compiled from 1153 
http://www.uwm.edu.pl/biochemia/index.php/en/biopep and http://omictools.com. 1154 
 1155 
Table 4. Milk protein-derived peptides identified in the gastrointestinal tract (GIT) of humans 1156 
following the ingestion of milk or dairy products. 1157 
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Table 1 1158 
Nature of the information Database/software Web page address 
Targets and drugs Therapeutic Target Database (TTD) http://bidd.nus.edu.sg/group/TTD/ttd.asp 
 Drug Bank http://www.drugbank.ca 
 Open Pharmacological Concepts Triple Store (Open 
PHACTS) Discovery Platform 
http://www.openphacts.org 
 ChEMBL https://www.ebi.ac.uk/chembl 
 Pubchem http://pubchem.ncbi.nlm.nih.gov 
 
Pathways WikiPathways http://www.wikipathways.org 
 Pathwaycommons. http://www.pathwaycommons.org 
 Biological Pathway Exchange (BioPAX) http://www.biopax.org/ 
 
Clinical trials ClinicalTrials.gov https://clinicaltrials.gov/ 
 
Workflow KNIME https://www.knime.org 
 Taverna http://www.taverna.org.uk 
 Pipeline Pilot http://accelrys.com/products/pipeline-
pilot/component-collections.html 
 myExperiment http://www.myexperiment.org 
 
Chemical compounds ZINC http://zinc.docking.org/  
 ChemDB http://cdb.ics.uci.edu./ 
 
Synthetic antimicrobial 
agents 
AMDDatabase http://www.amddatabase.info/index.html 
 1159 
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Table 2 1160 
Disease/health 
condition 
Target In vitro bioassay BAPs responsible for the activity 
Hypertension ACE ACE inhibition peptides with bulky and hydrophobic 
amino acids at the C- and N-terminus 
 renin  renin inhibition unknown 
 ROS DPPH, ABTS, SO and OH radical scavenging, 
ORAC, FRAP, TEAC, metal chelating 
Pro-, His-, Tyr-, Cys- and Trp-
containing peptides 
 erythrocytes anti-haemolytic activity in erythrocytes in cell 
cultures 
CMP 
 lipids lipid oxidation unknown 
Thrombosis platelet aggregation casoplatelin 
Type 2 diabetes insulin insulin secretion in pancreatic -cell cultures BCAA containing peptides  
 glycaemia n/a BCAA containing peptides 
 DPP-IV DPP-IV inhibition Trp- and X-Pro- containing peptides 
 incretin incretin secretion in cell cultures unknown 
 -glucosidase -glucosidase inhibition unknown 
 XO XO inhibition Trp-containing peptides 
Obesity satiety n/a GMP 
 fat/muscle mass in vitro muscle growth Leu, unknown 
 cholesterol bile acid-binding ability, cholesterol uptake and 
absorption in cell cultures 
Ile-Ile-Ala-Glu-Lys (lactostatin), His-
Ile-Arg-Leu (-lactostatin) 
 serotonin serotonin agonism in cell cultures Trp, unknown 
Cancer cancerous cells cell proliferation LFcin B, opiod peptides and CPPs 
 mutation cell proliferation unknown 
Osteoporosis bone osteoblast mineralisation in cell cultures, Ca 
mineralisation assays 
CPPs 
Anemia tissue and serum iron 
levels 
Fe mineralisation assays CPPs 
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Dental caries teeth teeth remineralisation, hydroxyapatite 
dissolution assay 
CPPs 
Infectious diseases pathogens microbial growth inhibition positively charged hydrophobic 
peptides, LFcin, CPPs 
Chronic & low-grade 
inflammation 
cytokines cytokines secretion in cell cultures CMP, CPPs, Arg-containing peptides 
 immune cells proliferation of immunomodulatory cells in 
cultures 
unknown 
Cognitive disease stress reduction neuromodulator (serotonin) secretion in cell 
cultures 
opioids, α-casozepine, Trp-containing 
peptides 
ABTS: 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid); ACE: angiotensin converting enzyme; BAPs: bioactive peptides; 1161 
BCAA: branched chain amino acid; CMP: caseinomacropeptide; CPPs: caseinophosphopeptides; DPP-IV: dipeptidyl peptidase IV; 1162 
DPPH: 2,2-diphenyl-1-picrylhydrazyl; FRAP: ferric ion reducing antioxidant power; GMP: glycomacropeptide; LFcin: lactoferricin; 1163 
n/a: not available; OH: hydroxyl; ORAC: oxygen radical absorbance capacity; ROS: reactive oxygen species; SO: superoxide; TEAC: 1164 
Trolox equivalent antioxidant capacity; XO: xanthine oxidase. 1165 
Adapted from Hernández-Ledesma et al. (2014); Nongonierma and FitzGerald (2015b); Shahidi and Zhong (2008) 1166 
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Table 3 1167 
Bioactivity Database/software Web page address Contents 
Diverse BIOPEP http://www.uwm.edu.pl/bio
chemia/index.php/en/biope
p 
bioactive peptide sequences, protein 
sequences, biological activity, peptide cutter, 
allergenic epitopes, sensory data on peptides 
 EROP-Moscow http://erop.inbi.ras.ru/ bioactive peptide sequences, activity, post-
translational modifications 
 PeptideDB http://www.peptides.be/ bioactive peptides and precursor proteins and 
peptides, search via key features of peptides, 
statistical analysis 
 PepBank http://pepbank.mgh.harvard
.edu/ 
cancer, cardiovascular diseases, diabetes, 
apoptosis, angiogenesis peptides 
ACE inhibition ACEpepDB http://www.cftri.com/pepdb
/index.php 
ACE inhibitory peptide sequences, biological 
activity, experimental conditions 
 AHTPDB http://crdd.osdd.net/raghava
/ahtpdb/ 
ACE inhibitory peptide sequences, biological 
activity, experimental conditions, toxicity 
Antimicrobial MilkAMP database http://milkampdb.org/home
.php 
AMPs from different milk sources, similarity 
searches, sequence alignment 
 Antimicrobial Peptide 
Database (APD) 
http://aps.unmc.edu/AP/mai
n.php 
AMPs and other bioactivities (e.g., 
antioxidant, anticancer, wound healing 
peptides), physicochemical properties, targets 
and mechanisms of action 
 AntiBP Server http://www.imtech.res.in/ra
ghava/antibp/index.html 
predictive tool for antibacterial peptides 
 Defensins Knowledgebase http://defensins.bii.a-
star.edu.sg/ 
defensin AMP 
 DADP http://split4.pmfst.hr/dadp/ Anuran defence peptides, biological activity 
 BACTIBASE http://bactibase.pfba-lab-
tun.org/main.php 
AMPs, physicochemical properties, targets 
and mechanisms of action 
 YADAMP http://www.yadamp.unisa.it AMPs (short -helix peptides interacting with 
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/default.aspx cell membranes), biological activity and 
structure  
 Dragon Antimicrobial 
Peptide Database 
(DAMPD) 
http://apps.sanbi.ac.za/dam
pd/BioTools.php 
AMPs, predictive tool for antimicrobial 
peptides 
 Collection of Anti-
Microbial Peptides 
(CAMP) 
http://www.camp.bicnirrh.r
es.in/ 
AMPs (experimental and predicted), 
predictive tool for antimicrobial peptides 
 PhytAMP http://phytamp.pfba-lab-
tun.org/main.php 
plant-derived AMP, sequence alignment and 
similarity searches 
 BTXpred Server http://www.imtech.res.in/ra
ghava/btxpred/ 
prediction of bacterial toxins, classification 
into endo/exotoxins, functionality of exotoxins 
 LAMP http://biotechlab.fudan.edu.
cn/database/lamp/ 
natural and synthetic AMPs 
 AMPer http://marray.cmdr.ubc.ca/c
gi-bin/amp.pl 
AMPs (experimental and predicted), similarity 
searches 
 RAPD http://faculty.ist.unomaha.e
du/chen/rapd/ 
recombinant AMPs  
 AVPdb http://crdd.osdd.net/servers/
avpdb/ 
AVPs, predictive tool for antiviral peptides 
 AVPpred http://crdd.osdd.net/servers/
avppred/ 
AVPs, predictive tool for antiviral peptides 
Anticancer ACPP http://acpp.bicpu.edu.in/ predictive tool for anticancer peptides 
 AntiCP http://crdd.osdd.net/raghava
/anticp/ 
predictive tool for anticancer peptides, peptide 
alignment, motif scan 
 CancerPPD http://crdd.osdd.net/raghava
/cancerppd/ 
anticancer peptides, peptide alignment 
 TumorHoPe http://crdd.osdd.net/raghava
/tumorhope/ 
tumor homing peptides 
 TumorHPD http://crdd.osdd.net/raghava
/tumorhpd/ 
prediction and design of tumor homing 
peptides 
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Others NeuroPep http://isyslab.info/NeuroPe
p/home.jsp 
neuropeptide database 
 SwePep http://www.swepep.org/ neuropeptides and hormones database 
 Brainpeps http://brainpeps.ugent.be/ blood-brain barrier peptide database 
 ParaPep http://crdd.osdd.net/raghava
/parapep/peptide.php 
antiparasitic peptides, similarity searches, 
alignment and mapping 
 SEMBA http://amyloid.cs.mcgill.ca/ prediction of binding affinity of amyloid 
proteins 
 WALTZ-DB http://waltzdb.switchlab.org
/ 
short peptides with amyloid fiber-forming 
capacities 
 CellPPD http://crdd.osdd.net/raghava
/cellppd/ 
predictive tool for cell penetrating peptides, 
motif scan 
 CPPsite http://crdd.osdd.net/raghava
/cppsite/ 
predicted tertiary and secondary structure for 
cell penetrating peptides, biological 
information 
 ConoServer http://www.conoserver.org/ peptides from carnivorous and marine cone 
snails 
 Quorumpeps http://quorumpeps.ugent.be
/ 
quorum sensing signalling peptides 
 Hmrbase http://crdd.osdd.net/raghava
/hmrbase/ 
hormones database 
 Hemolytik http://omictools.com/hemol
ytik-s6495.html 
heamolytic and non-heamolytic peptides 
 ToxinPred http://crdd.osdd.net/raghava
/toxinpred/ 
prediction and design of toxic and non-toxic 
peptides, analogue generation 
 Norine http://bioinfo.lifl.fr/norine/i
ndex.jsp 
non-ribosomal peptides, structure, biological 
activity 
 HIPdb http://crdd.osdd.net/servers/
hipdb/index.php 
HIV inhibiting peptides 
 BepiPred 1.0 Server http://www.cbs.dtu.dk/servi
ces/BepiPred/ 
prediction of the location of linear B-cell 
epitopes 
 VaxiJen http://www.ddg- prediction of protective antigens 
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pharmfac.net/vaxijen/VaxiJ
en/VaxiJen.html 
 BacGen http://ailab.ist.psu.edu/bacg
en/index.html 
predictive protective bacterial antigens 
 Peptide Design http://graal.ift.ulaval.ca/bioi
nformatics/peptide-design/ 
algorithm-based tool to predict the maximal 
bioactivity of peptides, prediction of binding 
to targets 
 PEP2D http://www.imtech.res.in/ra
ghava/pep2d/ 
prediction of 2D structure (helix and strand) of 
peptides 
 PSIPRED http://bioinf.cs.ucl.ac.uk/psi
pred/ 
prediction of 2D structure of peptides 
 PEPstr http://www.imtech.res.in/ra
ghava/pepstr/ 
prediction of 3D structure (-turn) of peptides 
 HLP http://www.imtech.res.in/ra
ghava/hlp/index.html 
prediction for the half-life of peptides with 
intestinal proteinases 
ACE: angiotensin converting enzyme; AMP: antimicrobial peptides; AVP: antiviral peptides; HIV: human immunodeficiency virus. 1168 
 1169 
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Table 4 1170 
Locus Parent 
protein
1
 
Fragment Peptide sequence
2
 Ingested 
sample 
Reported in vitro 
bioactivity
3
 
Reference 
Stomach -CN 1-12 RELEELNVPGEI milk or 
yoghurt 
- (Chabance et al., 1998) 
  6-17 LNVPGEIVESLS  -  
  29-40 KIEKFQSEEQQQ  -  
  29-41 KIEKFQSEEQQQT  -  
  30-41 IEKFQSEEQQQT  -  
  33-44 FQSEEQQQTEDE  -  
  94-105 GVSKVKEAMAPK  -  
  106-120 HKEMPFPKYPVEPFT  -  
  107-114 KEMPFPKY  -  
  164-175 SLSQSKVLPVPQ  -  
 s1-CN 4-15 HPIKHQGLPQEV  -  
  24-35 FVAPFPEVFGKE  -  
  25-32 VAPFPEVF  -  
  35-49 EKVNELSKDIGSEST  -  
  70-82 EIVPNSVEQKHIQ  -  
  120-131 LHSMKEGIHAQQ  -  
  143-149 AYFYPEL  ACE inhibitor  
  143-153 AYFYPELFRQF  -  
  180-191 SDIPNPIGSENS  -  
 -CN 106-116 MAIPPKKNQDK  platelet inhibitor  
  106-117 MAIPPKKNQDKT  platelet inhibitor  
  106-118 MAIPPKKNQDKTE  -  
  106-124 MAIPPKKNQDKTEIPTINT  -  
 53 
 
  147-161 EDSPEVIESPPEINT  -  
  106-169 caseinomacropeptide  immunomodulatory  
     -  
Intestine -CN 1-6 RELEEL CNs - (Boutrou et al., 2013) 
  1-11 RELEELNVPGE  -  
  1-12 RELEELNVPGEI  -  
  1-14 RELEELNVPGEIVE  -  
  2-12 ELEELNVPGEI  -  
  2-14 ELEELNVPGEIVE  -  
  3-14 LEELNVPGEIVE  -  
  4-11 EELNVPGE  -  
  4-12 EELNVPGEI  -  
  4-14 EELNVPGEIVE  -  
  5-11 ELNVPGE  -  
  5-12 ELNVPGEI  -  
  6-11 LNVPGE  -  
  6-12 LNVPGEI  -  
  6-13 LNVPGEIV  -  
  6-14 LNVPGEIVE  ACE inhibitor  
  7-12 NVPGEI  -  
  7-13 NVPGEIV  -  
  7-14 NVPGEIVE  ACE inhibitor   
  8-14 VPGEIVE  -  
  9-13 PGEIV  -  
  9-14 PGEIVE  -  
  33-48 FQSEEQQQTEDELQDK  -  
  41-51 TEDELQDKIHP  -  
  41-52 TEDELQDKIHPF  -  
  43-52 DELQDKIHPF  -  
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  45-50 LQDKISR  -  
  45-52 LQDKIHPF  -  
  46-52 QDKIHPF  -  
  47-52 DKIHPF  ACE inhibitor  
  57-66 SLVYPFPGPI  -  
  57-67 SLVYPFPGPIP  -  
  57-68 SLVYPFPGPIPN  -  
  57-72 SLVYPFPGPIHNSLPQ  -  
  58-66 LVYPFPGPI  -  
  58-67 LVYPFPGPIP  -  
  58-68 LVYPFPGPIPN  -  
  59-66 VYPFPGPI  ACE inhibitor, antiamnesic  
  59-67 VYPFPGPIP  ACE inhibitor, antiamnesic  
  59-68 VYPFPGPIPN  ACE-inhibitor  
  59-69 VYPFPGPIPNS  ACE-inhibitor  
  59-72 VYPFPGPIHNSLPQ  ACE-inhibitor  
  60-65 YPFPGP  opioid  
  60-66 YPFPGPI (-casomorphin-7)  opioid agonist, ACE-
inhibitor, 
immunomodulatory 
 
  60-67 YPFPGPIP  opioid agonist, ACE 
inhibitor 
 
  60-68 YPFPGPIPN  ACE and DPP-IV inhibitor  
  61-66 PFPGPI  -  
  61-67 PFPGPIP  -  
  61-68 PFPGPIPN  -  
  62-67 FPGPIP  -  
  62-68 FPGPIPN  DPP-IV inhibitor  
  63-68 PGPIPN  immunomodulatory  
  67-80 HNSLPQNIPPLTQT  -  
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  67-82 HNSLPQNIPPLTQTPV  -  
  67-91 HNSLPQNIPPLTQTPVVVPPFLQ
PE 
 -  
  67-92 HNSLPQNIPPLTQTPVVVPPFLQ
PEV 
 -  
  69-80 SLPQNIPPLTQT  -  
  69-82 SLPQNIPPLTQTPV  -  
  69-91 SLPQNIPPLTQTPVVVPPFLQPE  -  
  70-77 LPQNIPPL  DPP-IV inhibitor  
  70-78 LPQNIPPLT  -  
  70-80 LPQNIPPLTQT  -  
  70-82 LPQNIPPLTQTPV  -  
  71-77 PQNIPPL  DPP-IV inhibitor  
  71-78 PQNIPPLT  -  
  71-80 PQNIPPLTQT  -  
  71-91 PQNIPPLTQTPVVVPPFLQPE  -  
  71-92 PQNIPPLTQTPVVVPPFLQPEV  -  
  72-77 QNIPPL  -  
  73-77 NIPPL  -  
  73-78 NIPPLT  -  
  73-79 NIPPLTQ  -  
  73-80 NIPPLTQT  -  
  73-82 NIPPLTQTPV  ACE inhibitor  
  73-92 NIPPLTQTPVVVPPFLQPEV  -  
  74-80 IPPLTQT  -  
  74-82 IPPLTQTPV  DPP-IV inhibitor  
  74-91 IPPLTQTPVVVPPFLQPE  -  
  74-92 IPPLTQTPVVVPPFLQPEV  -  
  75-79 PPLTQ  -  
  75-82 PPLTQTPV  ACE inhibitor  
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  75-91 PPLTQTPVVVPPFLQPE  -  
  75-92 PPLTQTPVVVPPFLQPEV  -  
  80-86 TPVVVPP  -  
  80-87 TPVVVPPF  -  
  80-90 TPVVVPPFLQP  ACE inhibitor  
  80-91 TPVVVPPFLQPE  -  
  80-92 TPVVVPPFLQPEV  -  
  80-93 TPVVVPPFLQPEVM  -  
  81-86 PVVVPP  -  
  81-87 PVVVPPF  -  
  81-88 PVVVPPFL  -  
  81-89 PVVVPPFLQ  -  
  81-90 PVVVPPFLQP  -  
  81-91 PVVVPPFLQPE  -  
  81-92 PVVVPPFLQPEV  -  
  81-93 PVVVPPFLQPEVM  -  
  81-94 PVVVPPFLQPEVMG  -  
  82-87 VVVPPF  -  
  82-88 VVVPPFL  -  
  82-91 VVVPPFLQPE  -  
  82-92 VVVPPFLQPEV  -  
  83-87 VVPPF  -  
  83-91 VVPPFLQPE  -  
  83-92 VVPPFLQPEV  -  
  84-91 VPPFLQPE  -  
  84-92 VPPFLQPEV  -  
  85-89 PPFLQ  -  
  85-91 PPFLQPE  -  
  85-92 PPFLQPEV  -  
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  85-93 PPFLQPEVM  -  
  87-91 FLQPE  -  
  106-113 HKEMPFPK  -  
  106-114 HKEMPFPKY  -  
  106-119 HKEMPFPKYPVEPF  -  
  107-113 KEMPFPK  -  
  108-113 EMPFPK  hypotensive  
  108-114 EMPFPKY  -  
  109-113 MPFPK  -  
  114-119 YPVEPF  -  
  114-120 YPVEPFT  -  
  114-123 YPVEPFTESQ  -  
  115-119 PVEPF  -  
  115-120 PVEPFT  -  
  115-121 PVEPFTE  -  
  115-123 PVEPFTESQ  -  
  115-124 PVEPFTESQS  -  
  126-133 TLTDVENL  -  
  126-139 TLTDVENLHLPLPL  -  
  127-133 LTDVENL  -  
  128-133 TDVENL  -  
  128-138 TDVENLHLPLP  -  
  128-139 TDVENLHLPLPL  -  
  128-140 TDVENLHLPLPLL  -  
  129-138 DVENLHLPLP  -  
  129-139 DVENLHLPLPL  -  
  129-140 DVENLHLPLPLL  -  
  130-138 VENLHLPLP  -  
  130-139 VENLHLPLPL  -  
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  130-140 VENLHLPLPLL  anticancer  
  131-138 ENLHLPLP  ACE inhibitor  
  131-139 ENLHLPLPL  -  
  132-138 NLHLPLP  ACE inhibitor  
  132-140 NLHLPLPLL  anticancer  
  133-138 LHLPLP  ACE inhibitor  
  133-139 LHLPLPL  ACE inhibitor  
  133-140 LHLPLPLL  -  
  134-139 HLPLPL  antiamnesic  
  134-140 HLPLPLL  -  
  134-140 HLPLPLV  -  
  135-139 LPLPL  DPP-IV inhibitor  
  135-140 LPLPLL  -  
  140-148 LQSWMHQPH  -  
  142-148 SWMHQPH  -  
  143-148 WMHQPH  -  
  143-154 WMHQPHQPLPPT  -  
  143-155 WMHQPHQPLPPTV  -  
  144-154 MHQPHQPLPPT  -  
  144-155 MHQPHQPLPPTV  -  
  144-156 MHQPHQPLPPTVM  -  
  144-160 MHQPHQPLPPTVMFPPQ  -  
  144-161 MHQPHQPLPPTVMFPPQS  -  
  144-162 MHQPHQPLPPTVMFPPQSV  -  
  144-163 MHQPHQPLPPTVMFPPQSVL  -  
  145-154 HQPHQPLPPT  -  
  145-155 HQPHQPLPPTV  -  
  145-160 HQPHQPLPPTVMFPPQ  -  
  145-161 HQPHQPLPPTVMFPPQS  -  
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  145-162 HQPHQPLPPTVMFPPQSV  -  
  146-154 QPHQPLPPT  -  
  146-161 QPHQPLPPTVMFPPQS  -  
  146-162 QPHQPLPPTVMFPPQSV  -  
  148-154 HQPLPPT  -  
  148-161 HQPLPPTVMFPPQS  -  
  149-154 QPLPPT  -  
  149-155 QPLPPTV  -  
  149-160 QPLPPTVMFPPQ  -  
  156-160 MFPPQ  -  
  156-161 MFPPQS  -  
  168-175 SKVLPVPQ  hypotensive  
  170-174 VLPVP  -  
  170-175 VLPVPQ  -  
  170-176 VLPVPQK  antioxidant  
  170-182 VLPVPQKAVPYPQ  -  
  171-175 LPVPQ  -  
  176-182 KAVPYPQ  -  
  176-187 KAVPYPQRDMPI  -  
  177-182 AVPYPQ  -  
  183-187 RDMPI  -  
  190-206 LYQEPVLGPVRGPFPIL  -  
  191-201 LLYQEPVLGPV  immunostimulator (f 191-
193) 
 
  192-197 LYQEPV  -  
  192-201 LYQEPVLGPV  -  
  192-206 LYQEPVLGPVRGPFPIL  immunomodulatory, ACE-
inhibitor (f 193-202) 
 
  192-207 LYQEPVLGPVRGPFPI  immunomodulatory, ACE-
inhibitor (f 193-202) 
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  192-208 LYQEPVLGPVRGPFPII  immunomodulatory, ACE-
inhibitor (f 193-202) 
 
  193-199 YQEPVLG  immunomodulatory, ACE-
inhibitor (f 193-202) 
 
  193-201 YQEPVLGPV  ACE-inhibitor (f 193-198)  
  193-205 YQEPVLGPVRGPF  immunomodulatory, ACE-
inhibitor (f 193-202) 
 
  193-206 YQEPVLGPVRGPFP  immunomodulatory, ACE-
inhibitor (f 193-202) 
 
  193-207 YQEPVLGPVRGPFPI  immunomodulatory, ACE-
inhibitor (f 193-202) 
 
  194-201 QEPVLGPV  -  
  194-207 QEPVLGPVRGPFPI  -  
  194-208 QEPVLGPVRGPFPII  -  
  195-201 EPVLGPV  -  
  195-205 EPVLGPVRGPF  -  
  195-206 EPVLGPVRGPFP  -  
  195-207 EPVLGPVRGPFPI  -  
  195-208 EPVLGPVRGPFPII  -  
  196-201 PVLGPV  -  
  196-205 PVLGPVRGPF  -  
  196-206 PVLGPVRGPFP  -  
  196-207 PVLGPVRGPFPI  -  
  197-201 VLGPV  -  
  198-206 PVRGPFPIL  -  
  198-207 LGPVRGPFPI  -  
  198-208 LGPVRGPFPII  -  
  200-208 PVRGPFPII  -  
  1-12 RELEELNVPGEI Milk or 
yoghurt 
- (Chabance et al., 1998) 
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  7-16 NVPGEIVESL  -  
  7-18 NVPGEIVESLSS  -  
  69-80 SLPQNIPPLTQT  -  
  84-92 VPPFLQPEV  -  
  83-93 VVPPFLQPEVM  -  
  114-119 YPVEPF  -  
  145-156 HQPHQPLPPTVM  -  
  155-165 VMFPPQSVLSL  -  
  13-23 VESLS(P)S(P)S(P)EESIT cow’s milk or 
caseinophosph
opeptides 
mineral binding (Meisel et al., 2003) 
  60-63 YPFP (bovine -casomorphin-4) milk opioid (Svedberg et al., 1985) 
  60-65 YPFPGP (bovine -casomorphin-6)  -  
  60-66 YPFPGPI (bovine -casomorphin-
7) 
 opioid, ACE inhibitor  
 s1-CN 14-18 EVLNE milk or 
yoghurt 
- (Chabance et al., 1998) 
  25-32 VAPFPEVF  -  
  28-35 FPEVFGKE  -  
  106-114 VPQLEIVPN  -  
  133-138 EPMIGV  -  
  144-149 YFYPEL  ACE inhibitor, antioxidant  
  174-184 TDAPSFSDIPN  -  
 -CN 106-169 caseinomacropeptide milk proteins immunomodulatory (Ledoux et al., 1999) 
  106-115 MAIPPKKNQD milk or 
yoghurt 
- (Chabance et al., 1998) 
  107-113 AIPPKKN  -  
  107-115 AIPPKKNQD  -  
 -Lg 92-98 VLVLDTD whey proteins - (Boutrou et al., 2013) 
  92-99 VLVLDTDY  -  
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  92-103 VLVLDTDYKKYL  -  
  93-100 LVLDTDYK  -  
 LF 139-145 TESLEPL whey proteins - (Boutrou et al., 2013) 
  607-611 VKQVL  -  
  382-389 VLVLKGEA milk or 
yoghurt 
- (Chabance et al., 1998) 
  442-447 ANEGLT  -  
1-Lg: -lactoglobulin; CN: casein and LF: lactoferrin. 1171 
2
Peptide sequence abbreviated with the one letter amino acid code. 1172 
3
The bioactivity was obtained from the BIOPEP database and as per Nongonierma and FitzGerald (2015a). ACE: angiotensin 1173 
converting enzymes; DPP-IV: dipeptidyl peptidase IV. 1174 
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Figure captions 1175 
 1176 
Fig. 1. Schematic of the workflow commonly used in drug discovery and proposed reversed 1177 
workflow (from peptide identification in vivo to in vitro screening) for dietary peptide 1178 
identification and validation. 1179 
 1180 
Fig. 2. General recommendations to improve milk protein-derived bioactive peptide (BAP) 1181 
discovery. 1182 
 1183 
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